Omalizumab for urticaria treatment in clinical practice: a case series

INTRODUCTION: Omalizumab (Xolair) originally intended to reduce symptoms of moderate to severe asthma uncontrollable with steroids is the first monoclonal antibody approved for treatment of chronic spontaneous urticaria in 2014. AIM: To evaluate response and potential side effects to omalizumab trea...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Postepy Dermatol Alergol
Autori principali: Lesiak, Aleksandra, Bednarski, Igor A., Maćkowska, Anna, Łukasik, Zuzanna, Woźniacka, Anna, Olejniczak-Staruch, Irmina, Narbutt, Joanna
Natura: Artigo
Lingua:Inglês
Pubblicazione: Termedia Publishing House 2018
Soggetti:
Original Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6130138/
https://ncbi.nlm.nih.gov/pubmed/30206449
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/ada.2018.77666
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi